<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411082</url>
  </required_header>
  <id_info>
    <org_study_id>IMR-BTL-201</org_study_id>
    <secondary_id>2019-002989-12</secondary_id>
    <nct_id>NCT04411082</nct_id>
  </id_info>
  <brief_title>A Study of IMR-687 in Subjects With Beta Thalassemia</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects With Beta Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imara, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imara, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety,
      tolerability, PK, and PD of IMR-687 (phosphodiesterase (PDE) 9 inhibitor) administered once
      daily (qd) for 36 weeks in 2 populations of adult subjects with β-thalassemia: Population 1
      (Transfusion Dependent Thalassemia (TDT) subjects) and Population 2 (Non-Transfusion
      Dependent Thalassemia (NTDT) subjects).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with adverse events and serious adverse events</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Incidence of Adverse Events
Incidence of Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TDT Patients: Reduction in red blood cell (RBC) transfusion burden</measure>
    <time_frame>Week 12 through Week 36</time_frame>
    <description>Proportion of patients with ≥20% hematological improvement as compared to the 12 week prescreening timeframe
Proportion of patients with ≥33% hematological improvement as compared to the 12 week prescreening timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT Patients: Mean number of transfusion events</measure>
    <time_frame>Baseline to Week 36, Weeks 24 to 36</time_frame>
    <description>a. Mean number of transfusion events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT Patients: Mean change in ICT dose and Serum ferritin levels</measure>
    <time_frame>Baseline to Week 36, Weeks 24 to 36</time_frame>
    <description>a. Mean change in ICT dose and Serum ferritin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT Patients: Proportion of patients that had a decrease in ICT and serum ferritin as compared to the 12 week prescreening timeframe</measure>
    <time_frame>Baseline to Week 36, Weeks 24 to 36</time_frame>
    <description>a. Proportion of patients that had a decrease in ICT and serum ferritin as compared to the 12 week prescreening timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients:Mean change in HbF</measure>
    <time_frame>Baseline to Week 24, Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Mean change in HbF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients: Mean change in percent HbF</measure>
    <time_frame>Baseline to Week 24, Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Mean change in percent HbF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients: Mean change in HbF over a continuous 12-week interval in the absence of a transfusion</measure>
    <time_frame>Baseline to Week 24, Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Mean change in HbF over a continuous 12-week interval in the absence of a transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients: Subject Response in HbF (increase of ≥3%)</measure>
    <time_frame>Baseline to Week 24, Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Subject Response in HbF (increase of ≥3%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients: Mean change in Hb</measure>
    <time_frame>Baseline to Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Mean change in Hb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTDT Patients: Mean change in Hb over a continuous 12-week interval in the absence of a transfusion</measure>
    <time_frame>Baseline to Week 12 to 24, Week 24 to 36</time_frame>
    <description>a. Mean change in Hb over a continuous 12-week interval in the absence of a transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter Cmax</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter Area Under the Plasma Concentration versus Time Curve (AUC)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Area Under the Plasma Concentration versus Time Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter Tmax</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Time to maximum concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter t ½</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Apparent terminal half-life t ½ (half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter AUC 0-24</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Area Under the Plasma Concentration versus Time Curve (AUC) from time 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter AUClast</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. 0 to the last measurable timepoint (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDT and NTDT Patients: PK Parameter AUC 0-infinity</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>a. Extrapolated to infinity (AUC0-∞)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>β Thalassemia</condition>
  <arm_group>
    <arm_group_label>Lower Dose IMR-687</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of once daily IMR-687</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose IMR-687</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of once daily IMR-687</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of once daily placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMR-687</intervention_name>
    <description>Oral administration of once daily IMR-687</description>
    <arm_group_label>Higher dose IMR-687</arm_group_label>
    <arm_group_label>Lower Dose IMR-687</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of once daily Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented diagnosis of β-thalassemia or HbE/ β-thalassemia. Concomitant single alpha
             gene deletion, duplication, or triplication is allowed.

          2. Documentation of dates of transfusions and the number of all RBC units within the 12
             weeks prior to Screening.

          3. Must be willing and able to complete all study assessments and procedures, and to
             communicate effectively with the investigator and site staff.

          4. ECOG performance score of 0-1

          5. Female subjects must not be pregnant, not be breast feeding, and be highly unlikely to
             become pregnant. Male subjects must be unlikely to impregnate a partner.

        Exclusion Criteria:

          1. Diagnosis of α-thalassemia (e.g., hemoglobin H [HbH]) or hemoglobin S (HbS)/ β
             thalassemia.

          2. Body mass index (BMI) &lt;17.0 kg/m2 or a total body weight &lt;45 kg; or BMI &gt;35 kg/m2

          3. Subjects with known active hepatitis A, hepatitis B, or hepatitis C, with active or
             acute event of malaria, or who are known to be positive for human immunodeficiency
             virus (HIV).

          4. Stroke requiring medical intervention ≤24 weeks prior to randomization.

          5. Platelet count &gt;1000 × 109/L.

          6. Subjects on iron chelation therapy (ICT) at the time of ICF signing must have
             initiated the treatment with ICT at least 24 weeks before the predicted randomization
             date.

          7. Prior exposure to sotatercept, luspatercept, IMR-687, or gene therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omkar Marathe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Oncology Institute Long Beach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleanor Lisbon, MD, MPH</last_name>
    <phone>913-449-4319</phone>
    <email>elisbon@imaratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Cyr</last_name>
    <phone>617-206-2020</phone>
    <email>trials@imaratx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omkar Marathe, MD</last_name>
      <phone>562-232-0550</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transfusion</keyword>
  <keyword>TDT</keyword>
  <keyword>NTDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

